Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

Feb 08, 2018
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasis-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-receives-fda-approval-cosentyx-label-update-include-moderate-severe-scalp-psoriasis-0